ELTX · Insider Trading
Elicio Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by ELTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Carol Gail Ashe | Director | A | +21,750 deriv. | — |
| 2026-09-02 | Yekaterina Chudnovsky | Director | A | +21,750 deriv. | — |
| 2026-09-02 | Jay Venkatesan | Director | A | +21,750 deriv. | — |
| 2026-09-02 | Robert R Ruffolo | Director | A | +21,750 deriv. | — |
| 2026-09-02 | Julian Adams | Director | A | +21,750 deriv. | — |
| 2026-09-02 | Allen Nissenson | Director | A | +21,750 deriv. | — |
| 2026-09-02 | Karen J Wilson | Director | A | +21,750 deriv. | — |
| 2026-07-17 | Peter DeMuth | Chief Scientific Officer | A | +52,832 deriv. | — |
| 2026-07-17 | Robert Connelly | CEO, President and Director | A | +186,944 deriv. | — |
| 2026-07-17 | Christopher Haqq | See Remarks | A | +64,643 deriv. | — |
| 2026-07-17 | Preetam Shah | See Remarks | A | +60,833 deriv. | — |
| 2026-02-03 | Preetam Shah | See Remarks | A | +24,000 | — |
| 2026-02-03 | Robert Connelly | CEO, President and Director | A | +73,600 | — |
| 2026-02-03 | Christopher Haqq | See Remarks | A | +25,400 | — |
| 2026-02-03 | Peter DeMuth | Chief Scientific Officer | A | +20,800 | — |
| 2025-12-10 | Peter DeMuth | Chief Scientific Officer | M | +362 | +$1.60K |
| 2025-06-04 | GKCC, LLC | 10%+ Owner | A | +206,450 deriv. | — |
| 2025-05-20 | Allen Nissenson | Director | A | +7,900 deriv. | — |
| 2025-05-20 | Carol Gail Ashe | Director | A | +7,900 deriv. | — |
| 2025-05-20 | Karen J Wilson | Director | A | +7,900 deriv. | — |
| 2025-05-20 | Robert R Ruffolo | Director | A | +7,900 deriv. | — |
| 2025-05-20 | Julian Adams | Director | A | +7,900 deriv. | — |
| 2025-05-20 | Jay Venkatesan | Director | A | +7,900 deriv. | — |
| 2025-05-20 | Yekaterina Chudnovsky | Director | A | +7,900 deriv. | — |
| 2025-04-16 | Preetam Shah | See Remarks | A | +191,624 deriv. | — |
| 2025-03-07 | GKCC, LLC | 10%+ Owner | C | +7,001,146 | +$40.68M |
| 2025-02-04 | Robert Connelly | CEO, President and Director | A | +121,600 deriv. | — |
| 2025-02-04 | Christopher Haqq | See Remarks | A | +44,000 deriv. | — |
| 2025-02-04 | Peter DeMuth | Chief Scientific Officer | A | +44,400 deriv. | — |
| 2025-01-02 | Jay Venkatesan | Director | Buy | +100,000 deriv. | — |
| 2024-12-18 | Peter DeMuth | Chief Scientific Officer | M | +381 | +$1.68K |
| 2024-11-29 | Jay Venkatesan | Director | X | +50,000 | +$500 |
| 2024-11-25 | Yekaterina Chudnovsky | Director | A | +4,100 deriv. | — |
| 2024-11-25 | Jay Venkatesan | Director | A | +4,100 deriv. | — |
| 2024-11-25 | Robert R Ruffolo | Director | A | +4,100 deriv. | — |
| 2024-11-25 | Carol Gail Ashe | Director | A | +4,100 deriv. | — |
| 2024-11-25 | Allen Nissenson | Director | A | +4,100 deriv. | — |
| 2024-11-25 | Julian Adams | Director | A | +4,100 deriv. | — |
| 2024-11-25 | Karen J Wilson | Director | A | +4,100 deriv. | — |
| 2024-10-02 | Robert Connelly | CEO, President and Director | A | +91,600 deriv. | — |
| 2024-10-02 | Christopher Haqq | See Remarks | A | +28,200 deriv. | — |
| 2024-10-02 | Peter DeMuth | Chief Scientific Officer | A | +29,800 deriv. | — |
| 2024-08-14 | Yekaterina Chudnovsky | Director | Buy | +6,884,682 deriv. | — |
| 2024-07-02 | Jay Venkatesan | Director | Buy | +200,000 deriv. | — |
| 2024-07-02 | GKCC, LLC | 10%+ Owner | Buy | +6,400,000 deriv. | — |
| 2024-03-20 | GKCC, LLC | 10%+ Owner | Buy | +2,065,404 deriv. | — |
| 2024-02-05 | Christopher Haqq | See Remarks | A | +28,200 deriv. | — |
| 2024-02-05 | Robert Connelly | CEO, President and Director | A | +225,137 deriv. | — |
| 2024-02-05 | Peter DeMuth | Chief Scientific Officer | A | +30,142 deriv. | — |
| 2024-02-05 | Brian Piekos | Chief Financial Officer | A | +43,225 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| GKCC, LLC | 10%+ Owner | 5,416,212 | $8.58M |
| Jay Venkatesan | Director | 180,534 | $286.15K |
| Robert Connelly | CEO, President and Director | 120,570 | $191.10K |
| Christopher Haqq | See Remarks | 57,381 | $90.95K |
| Preetam Shah | See Remarks | 24,000 | $38.04K |
| Peter DeMuth | Chief Scientific Officer | 21,543 | $34.15K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ELTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.